New therapies and diagnostics offer great opportunities, but also raise significant questions regarding which tests to offer, how to integrate these into existing organizations and regular clinical practice, and how to ensure broad access to cutting-edge therapies while maintaining sufficient diagnostic safety and quality.
As part of the BigMed project we aimed to identify the organizational structures, processes, and systems that both contribute to and prevent broad NGS-based cancer testing across Nordic hospitals. Through a series of structured workshops and in-depth interviews with stakeholders from institutions across the Nordics, we describe common trends and generalized learnings synthesized from their unique journeys. Our hope is that this work can give visibility to the shared challenges, and can give insight into paths forward that enable more effective implementations of molecular diagnostics and ultimately better cancer care.
Read more by downloading the positition paper - see form above.